ৰেক্তেল কেন্সাৰ
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
ক’ত যাব
এই ট্ৰায়েলৰ বাবে ভাৰতৰ 5 খন হস্পিতালত ৰোগী লোৱা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type…
প্ৰযোজক: Janssen Research & Development, LLC
NCT06662786 on ClinicalTrials.gov
পঞ্জীত শেষবাৰৰ বাবে 25 Sep 2026 তাৰিখে আপডেট কৰা হৈছে · আমাৰ দ্বাৰা 20 Oct 2026 তাৰিখে পঢ়া হৈছে